34,662 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by Aigen Investment Management LP

Key Points

• Aigen Investment Management LP acquired a new position in Hologic, Inc. during the 1st quarter, purchasing 34,662 shares valued at approximately $2,141,000.
• Hologic reported a quarterly earnings EPS of $1.08, exceeding analysts' estimates, with quarterly revenue rising by 1.2% year-over-year to $1.02 billion.
• Institutional investors collectively hold 94.73% of Hologic's shares, indicating strong institutional confidence in the company.

Aigen Investment Management LP purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 34,662 shares of the medical equipment provider's stock, valued at approximately $2,141,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in HOLX. Victory Capital Management Inc. increased its position in shares of Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after purchasing an additional 1,692,177 shares during the last quarter. Champlain Investment Partners LLC purchased a new position in Hologic in the 4th quarter worth $79,291,000. Redwood Wealth Management Group LLC purchased a new position in Hologic in the 1st quarter worth $3,534,000. Invesco Ltd. lifted its stake in Hologic by 18.8% in the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after purchasing an additional 764,573 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Hologic by 26.9% during the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock valued at $226,898,000 after buying an additional 668,086 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on HOLX shares. Raymond James Financial restated an "outperform" rating and set a $71.00 target price (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price target for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Citigroup raised shares of Hologic from a "neutral" rating to a "buy" rating and upped their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Evercore ISI raised their target price on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research note on Tuesday, July 8th. Finally, UBS Group boosted their price target on Hologic from $65.00 to $70.00 and gave the company a "neutral" rating in a report on Thursday, July 31st. Ten research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $77.83.

Hologic Stock Down 1.3%

Shares of NASDAQ:HOLX traded down $0.88 on Thursday, hitting $68.10. 603,234 shares of the company traded hands, compared to its average volume of 2,792,739. The stock has a 50 day simple moving average of $65.43 and a 200-day simple moving average of $62.69. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The company has a market cap of $15.15 billion, a PE ratio of 28.26, a PEG ratio of 2.47 and a beta of 0.49. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.06 earnings per share. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.